Spots Global Cancer Trial Database for omacetaxine
Every month we try and update this database with for omacetaxine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate | NCT01844869 | Hematologic Mal... Solid Tumors | omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors | NCT00675350 | Hematologic Tum... | Omacetaxine | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) | NCT04926285 | Relapsed or Ref... | Omacetaxine Venetoclax | 18 Years - 75 Years | University of Illinois at Chicago | |
| Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01272245 | Leukemia | Omacetaxine Cytarabine | 60 Years - | M.D. Anderson Cancer Center | |
| Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | NCT00114959 | Myeloid Leukemi... Myeloid Leukemi... Blast Phase Myeloid Leukemi... | Homoharringtoni... Imatinib Mesyla... | 16 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT02141477 | Leukemia | Omacetaxine Decitabine | 70 Years - | M.D. Anderson Cancer Center | |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) | NCT02835794 | Myelodysplastic... | Omacetaxine Azacitidine G-CSF | 18 Years - | University of Florida | |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | NCT00462943 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors | NCT00675350 | Hematologic Tum... | Omacetaxine | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | NCT00462943 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
